Category Archives: Inside BIO Industry Analysis

Nasdaq Social Bell: Twitter Strategies For Biotechs

Nasdaq Social Bell

Last week at the BIO CEO & Investor Conference in New York City, I had the pleasure of speaking with John Machiz and Brad Smith from Nasdaq at their headquarters in Times Square to discuss the social media activity that happened onsite during the event, what made the discussion of the event online so robust, and what biotech companies can do to increase their visibility on Twitter. View the video below, and get a recap of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Deal Structures: More Options for Companies

CEO2013_115x75_Thumbnail copy

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal values, , licensing values and volume were all up, as were big pharma M&A deals and asset swaps. What do these trends mean for dealmakers in 2015? Answering that question was the task of a panel at the 2015 BIO CEO & Investor Conference, Emerging Trends in Deal Structures. Moderated by Fenwick and West’s Effie Toshav, the panel included: Bruce Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Ten Years of Therapeutic Venture Capital

vc-blog

What therapeutic areas have received the most funding in private drug companies over the last decade? How much of this has been for new drugs vs drug delivery? How much into biologics vs small molecules? This week, we released a first-of-its-kind, comprehensive report on venture capital trends covering 2004-2013. To investigate investor trends in specific therapeutic areas and level of innovation, we analyzed data from four venture capital databases to create the broadest, most comprehensive Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?

TheHill

Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several of the arguments frequently made in recent debates about the price and value of innovative medicines. Philipson argues that physicians are often self-interested as buyers when complaining about drug prices, and often fail to understand the broader economic context in which drug pricing decisions must be made: “Just as you wouldn’t let a financial planner perform cancer surgery, we shouldn’t Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Announcing the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey

lab_tech

Click here for the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey. Your investment plans and budgets all include growth assumptions and market forecasts. Can you trust them? 2014 was another banner year for biotech IPOs, with 81 companies in our industry going public, an increase of nearly 90 percent over 2013. Now we turn our attention to the year ahead and what we can expect. More blue skies or dark clouds?  M&A surpassing last year Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,